Rheumatoid Arthritis

ICD-11: FA20

Disease Overview

Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by symmetric inflammatory polyarthritis, joint destruction, and systemic manifestations. Pathophysiology involves autoimmune attack on synovium, with HLA-DRB1 shared epitope, citrullinated peptide recognition, and TNF/IL-6–driven inflammation. Seropositive RA (RF and/or anti-CCP) has stronger genetic component than seronegative. Heritability is ~60%; SNP-based h² is ~0.13. HLA-DRB1 contributes ~30% of genetic variance. Key genes include HLA-DRB1 (antigen presentation), PTPN22 (T-cell signaling), and loci in TNF pathway. Smoking, particularly in HLA-DRB1 carriers, dramatically increases anti-CCP–positive RA risk via citrullination. Infections, obesity, and reproductive factors may modify risk. Early diagnosis and DMARD therapy prevent joint damage.

RA onset typically occurs in adulthood but juvenile idiopathic arthritis (JIA) presents in childhood. Ages 10–24 may see JIA persistence or transition to adult RA. Smoking initiation during adolescence increases future RA risk, especially in genetically susceptible individuals. Obesity in youth may amplify risk. Psychosocial stress and physical activity patterns established in adolescence may influence disease course. Genetic risk assessment in adolescents is generally not indicated; family history may inform monitoring.

Genetic Architecture Summary

GeneVariantGWAS pEvidenceStrength
HLA-DRB1Shared epitope alleles1.0e-100MHC class II; antigen presentation; shared epitope hypothesis; citrullinated peptide presentation; strongest RA locus0.98
PTPN22rs24766011.0e-40Lymphoid tyrosine phosphatase; T-cell receptor signaling; multiple autoimmune diseases0.88
TNFrs18006291.0e-15TNF-alpha; central cytokine in RA pathogenesis; anti-TNF therapeutics0.85
CTLA4rs30872431.0e-10T-cell costimulation; immune checkpoint; autoimmune susceptibility0.75

Heritability

h² SNP: 0.13; h² narrow-sense: 0.6 EIRA and large RA GWAS meta-analyses (2019)

PRS notes: RA PRS show moderate predictive ability (AUC ~0.65–0.72). HLA contributes substantially. Transferability is limited: European discovery; HLA structure varies by ancestry. PRS may stratify risk in preclinical phases; utility for screening in general population is limited. G×E (smoking–HLA interaction) is well-established but not fully integrated into PRS.

Exposure Modifier Panel

ExposureDirectionStrengthConfidenceMechanism hypothesis
tobaccoamplify0.95HIGHSmoking induces citrullination in lungs; in HLA-DRB1 carriers, dramatically increases anti-CCP–positive RA risk; gene–environment interaction
obesity-exposureamplify0.7HIGHAdipose-derived cytokines (leptin, adiponectin) promote inflammation; obesity increases RA risk and reduces treatment response
psychosocial-stressamplify0.55MEDIUMStress may trigger or exacerbate RA flares; affects disease activity and treatment adherence
diet-qualitybuffer0.5MEDIUMMediterranean diet, omega-3 fatty acids may reduce inflammation; observational evidence for symptom improvement

Population Equity Notes

GWAS ancestry breakdown: RA GWAS are predominantly European (~85%); multi-ancestry efforts are expanding

Transferability notes: HLA associations vary by ancestry; shared epitope alleles differ in frequency. PTPN22 risk allele is rare in East Asians. PRS performance in non-European populations is reduced.

Data gaps: Under-representation of diverse ancestries; G×E (smoking–HLA) across populations; seronegative RA genetics; preclinical phase prediction.

Tissue Context

synovium0.98
immune cells (T and B lymphocytes)0.95
lung (for citrullination)0.85
adipose tissue0.75

Visualizations

Risk Shift by Exposure Stratum

Population-level data only — does not predict individual risk

Tissue Relevance

References

  1. 1.Okada Y, et al. (2014). Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. doi:10.1038/nature12873
  2. 2.Källberg H, et al. (2007). A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis & Rheumatology. doi:10.1002/art.22795
  3. 3.Bottini N, Peterson EJ (2014). PTPN22 and autoimmune disease. Nature Reviews Immunology. doi:10.1038/nri3660
  4. 4.Stavropoulos-Kalinoglou A, et al. (2013). Obesity and rheumatoid arthritis. Nature Reviews Rheumatology. doi:10.1038/nrrheum.2013.36
  5. 5.Matcham F, et al. (2014). Stress and rheumatoid arthritis. Journal of Psychosomatic Research. doi:10.1016/j.jpsychores.2014.03.002